Stockscreener 앱 받기
1.41
7.24%
-0.11
시장 영업 전:
1.50
0.09
+6.38%
전일 마감가:
$1.52
열려 있는:
$1.53
하루 거래량:
1.20M
Relative Volume:
0.61
시가총액:
$99.69M
수익:
-
순이익/손실:
$-144.01M
주가수익비율:
-0.3516
EPS:
-4.01
순현금흐름:
$-113.02M
1주 성능:
+15.57%
1개월 성능:
+2.92%
6개월 성능:
-45.98%
1년 성능:
-75.69%
1일 변동 폭
$1.41
$1.54
1주일 범위
$1.19
$1.56
52주 변동 폭
$0.8719
$6.06
바이오미아 퓨전 Stock (BMEA) Company Profile
명칭
Biomea Fusion Inc
전화
(650) 980-9099
주소
1599 INDUSTRIAL ROAD, SAN CARLOS
BMEA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BMEA
Biomea Fusion Inc
|
1.41 | 107.47M | 0 | -144.01M | -113.02M | -4.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
바이오미아 퓨전 Stock (BMEA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-28 | 개시 | Jefferies | Buy |
| 2025-06-03 | 재개 | Piper Sandler | Overweight |
| 2024-10-09 | 개시 | Edward Jones | Buy |
| 2024-09-27 | 업그레이드 | Rodman & Renshaw | Neutral → Buy |
| 2024-09-27 | 업그레이드 | Truist | Hold → Buy |
| 2024-08-29 | 개시 | CapitalOne | Overweight |
| 2024-06-11 | 다운그레이드 | Truist | Buy → Hold |
| 2024-06-07 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2024-04-02 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-02-06 | 개시 | Truist | Buy |
| 2023-07-27 | 개시 | Scotiabank | Sector Outperform |
| 2023-06-26 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-05-12 | 개시 | Barclays | Overweight |
| 2023-03-29 | 재확인 | Oppenheimer | Outperform |
| 2023-03-28 | 재확인 | H.C. Wainwright | Buy |
| 2023-02-24 | 개시 | Citigroup | Buy |
| 2022-06-02 | 재개 | H.C. Wainwright | Buy |
| 2022-01-12 | 개시 | H.C. Wainwright | Buy |
| 2021-12-17 | 개시 | Oppenheimer | Outperform |
| 2021-05-11 | 개시 | JP Morgan | Overweight |
| 2021-05-11 | 개시 | Jefferies | Buy |
| 2021-05-11 | 개시 | Piper Sandler | Overweight |
모두보기
바이오미아 퓨전 주식(BMEA)의 최신 뉴스
JANUS HENDERSON GROUP PLC Acquires Significant Stake in Biomea Fusion Inc - GuruFocus
Interim CEO & Director of Biomea Fusion Michael J. Hitchcock Buys 667% More Shares - simplywall.st
Biomea Fusion Announces KOL Presentation and Interview on Menin and Icovamenib at WCIRDC 2025 - The Manila Times
Biomea Fusion Highlights the Future of Menin Inhibitors and Icovamenib in Interview with Dr. Ralph DeFronzo at WCIRDC 2025 - Quiver Quantitative
Biomea Fusion (Nasdaq: BMEA) features KOL talk on menin, icovamenib at WCIRDC 2025 - Stock Titan
Biomea Fusion : WCIRDC 2025 COVALENT 111 Week 52 final Oral Presentation - marketscreener.com
Is Biomea Fusion Inc a good long term investmentEarnings Revision Updates & High Profit Market Growth - earlytimes.in
Biomea Fusion presents COVALENT-111 study results at WCIRDC - MSN
Biomea Fusion reports durable effects of diabetes drug 9 months after dosing - Investing.com Nigeria
Biomea Fusion (BMEA) Stock Jumps on Durable Diabetes Drug Data: Outlook, Analyst Targets and Key Risks as of December 5, 2025 - ts2.tech
Biomea Fusion Showcases Durable Benefits Of Menin Inhibitor In Type-2 Diabetes - RTTNews
Biomea Fusion stock soars after durable diabetes treatment results By Investing.com - Investing.com Nigeria
Biomea Fusion stock soars after durable diabetes treatment results - Investing.com
Biomea Fusion reports durable effects of diabetes drug 9 months after dosing By Investing.com - Investing.com South Africa
Biomea Fusion Presents Promising Results for Icovamenib in Treating Type 2 Diabetes at WCIRDC 2025 - Quiver Quantitative
Biomea Fusion Presents COVALENT-111 Study Results at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) - The Manila Times
Is Biomea Fusion Inc. stock a buy before product launchesEarnings Recap Report & Weekly Top Gainers Alerts - Newser
BMEA Insider Trading - Quiver Quantitative
Biomea Fusion Interim CEO Increases Stake with 100,000 Shares Purchase - TradingView
BMEA: Advancing Menin and oral GLP-1 therapies for diabetes, with phase II trials and strong financial runway - TradingView — Track All Markets
Biomea Fusion (BMEA) Stock Analysis Report | Financials & Insights - Benzinga
Biomea Fusion Director Rainer M Erdtmann Acquires 50,000 Shares - TradingView
Biomea Fusion, Inc. (NASDAQ:BMEA) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Biomea Fusion to present long-term diabetes drug data at WCIRDC - Investing.com Canada
Biomea Fusion announces breakthrough data presentation at WCIRDC - Traders Union
Biomea Fusion to Present Long-Term Icovamenib Data at 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease - Quiver Quantitative
Biomea Fusion Announces Oral Presentation of Icovamenib at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) - The Manila Times
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Biomea Fusion (Nasdaq: BMEA) to present icovamenib β-cell data in insulin-deficient T2D - Stock Titan
Biomea Fusion (Nasdaq: BMEA) Grants 7,500-Share Inducement Option to New Employee - Stock Titan
Aisling Capital Management LP Purchases 1,250,000 Shares of Biomea Fusion, Inc. $BMEA - MarketBeat
Published on: 2025-11-30 10:58:22 - BỘ NỘI VỤ
Biomea Fusion Inc Stock Analysis and ForecastMoving Average Crossovers & Capital Allocation Recommendations - earlytimes.in
Why analysts remain bullish on Biomea Fusion Inc. stock2025 Market Trends & Real-Time Buy Signal Notifications - moha.gov.vn
Form 8-KCurrent report - ADVFN
Can Biomea Fusion Inc. stock outperform in 2025 bull marketTrade Entry Summary & Free Weekly Watchlist of Top Performers - BỘ NỘI VỤ
Will Biomea Fusion Inc. stock return to pre crisis levelsJuly 2025 Catalysts & Long-Term Safe Return Strategies - BỘ NỘI VỤ
Biomea Fusion set to engage at major investor conferences - Traders Union
Biomea Fusion (BMEA) Price Target Decreased by 10.64% to 7.14 - MSN
Biomea Fusion to Participate at Upcoming Investor Conferences - Investing News Network
Is the Smart Money Moving Into 52 Weeks Entertainment Limited Institutional Buying TrendsTechnical Analysis Insights & Fast Growing Investment Ideas - earlytimes.in
Biomea Fusion downgraded to Underweight from Neutral at JPMorgan - MSN
Is Biomea Fusion Inc. a candidate for recovery playBreakout Watch & Capital Efficient Trade Techniques - newser.com
Is Biomea Fusion Inc. stock a dividend growth opportunity2025 Key Highlights & High Accuracy Buy Signal Tips - newser.com
Why Biomea Fusion Inc. stock could be next big winnerEarnings Overview Report & Low Risk High Win Rate Picks - newser.com
바이오미아 퓨전 (BMEA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.08%
0.91%
자본화:
|
볼륨(24시간):